New Market Study Published: Singapore Pharmaceuticals & Healthcare Report Q1 2011

Recently published research from Business Monitor International, "Singapore Pharmaceuticals & Healthcare Report Q1 2011", is now available at Fast Market Research
Spread the Word
Listed Under

* Patent
* Disease
* Healthcare
* Property
* Ratings
* Asia
* Protection
* Burden
* Medicines
* Intellectual

* Health
* Medical
* Research

* Massachusetts - US

Dec. 31, 2010 - PRLog -- Demographic and epidemiological factors will shape the development of the Singaporean pharmaceutical market over the coming years. The city-state's population is ageing rapidly and increasingly suffering from conditions such as diabetes and obesity-related problems, which require long-term treatment. According to the latest National Health Survey, the obesity rate in Singapore rose to 10.8% during 2010, up from the 6.9% recorded in 2004. The Health Promotion Board (HPB) attributed the rising rate to a lack of physical activity coupled with a more sedentary lifestyle. The alarming rise has led the government to launch the National Healthy Lifestyle campaign.

In local currency terms, Singapore's pharmaceutical market is forecast to reach SGD839mn (US$615mn) in 2010, thus rising by a low single-digit figure in relation to the calculated 2009 value. The market will post a local currency compound annual growth rate (CAGR) of 3.80% in the 2009-14 period, which will be characterised by the increased use of generics (with Indian firms to benefit from an improved registration pathway), patent expirations and a general focus on cost-containment. Growth figures will improve in the subsequent five years, with the market posting a 4.76% CAGR over the 2009-2019 period, reaching SGD1.31bn (US$1.03bn).

However, despite some positives, Singapore slipped from fourth to sixth place in BMI's Asia Pacific Pharmaceutical Business Environment Ratings (BER) for Q111. While Singapore's consistent and transparent medicine regulations are attractive to multinational drugmakers, its fundamental drawback is a small and mature pharmaceutical market that is growing slowly, while strict price controls are also a deterrent. Over the medium term, we expect Singapore to fall down the ratings, as emerging countries such as Vietnam and Indonesia become more alluring to foreign firms selling patented products.

Nevertheless, Singapore's commitment to a low tax regime and high levels of investment in its infrastructure ensures that it has a superior business environment not only among its regional peers, but across the world. The authorities are aiming to boost its biotechnology industry, which will continue to provide a steady and expanding stream of pharmaceutical exports. The government is dedicated to attracting skilled migrants and foreign direct investment (FDI) in order to maintain its pre-eminence as a regional trade and financial hub, as well as enabling the economy to diversify into service industries. All this is being achieved in an environment of low corruption, minimal bureaucracy and good security, which will continue to provide strong attractions for foreign pharmaceutical companies.

For more information or to purchase this report, go to:

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Singapore Pharmaceuticals And Healthcare Industry SWOT
- Singapore Political SWOT
- Singapore Economic SWOT
- Singapore Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q111
- Rewards
- Risks
Singapore - Market Summary
- Regulatory Regime
- Intellectual Property Issues
- Trade Agreements
- Pricing and Reimbursement
Industry Trends and Developments
- Epidemiology
- Non-Communicable Disease
- Communicable Disease
- Healthcare Sector
- Healthcare Financing
- Healthcare Insurance Developments
- Healthcare Company Developments
- Medical Tourism
- Research and Development
- Bioscience Sector
- Recent Research and Development Activities
- Clinical Trials
- Recent Developments in Clinical Trials Industry
- Medical Devices
- Table: Classification Of Medical Devices In Singapore
- Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
- Key Growth Factors - Macroeconomic
- Table: Singapore - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2006-2014
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2006-2014
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation
- Domestic Pharmaceutical Sector
- Domestic Pharmaceutical Output
- Foreign Industry
- Foreign Company Activities
- Traditional Chinese Medicine
- Pharmaceutical Distribution
- Retail Pharmacies
- Recent Developments in Pharmaceutical Supply Chain
Company Profiles
- Indigenous Manufacturers
- Haw Par
- SciGen
- MerLion Pharmaceuticals
- Veredus Laboratories
- Leading Multinationals
- Pfizer
- Novartis
- GlaxoSmithKline
- Sanofi-Aventis
- Merck & Co
- Baxter
Country Snapshot: Singapore Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2000-2030
- Section 2: Education and Healthcare
- Table: Education, 2000-2004
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts

Full Table of Contents is available at:

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Patent, Disease, Healthcare, Property, Ratings, Asia, Protection, Burden, Medicines, Intellectual
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share